U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals, in a deal that could worth more than $15 billion.
About the Author
Discover more from InfoVera USA
Subscribe to get the latest posts sent to your email.
